475 related articles for article (PubMed ID: 10945877)
21. Characterization of kappa and delta opioid receptors in isolated organs by using type/subtype selective agonists and antagonists.
Makó E; Rónai AZ
Med Sci Monit; 2001; 7(3):350-6. PubMed ID: 11386008
[TBL] [Abstract][Full Text] [Related]
22. Activity of mu- and delta-opioid agonists in vas deferens from mice deficient in MOR gene.
Maldonado R; Severini C; Matthes HW; Kieffer BL; Melchiorri P; Negri L
Br J Pharmacol; 2001 Apr; 132(7):1485-92. PubMed ID: 11264242
[TBL] [Abstract][Full Text] [Related]
23. Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective mu/kappa antagonist in the [35S]-GTP-gamma-S functional binding assay.
Romero DV; Partilla JS; Zheng QX; Heyliger SO; Ni Q; Rice KC; Lai J; Rothman RB
Synapse; 1999 Nov; 34(2):83-94. PubMed ID: 10502307
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological Properties of
Dripps IJ; Chen R; Shafer AM; Livingston KE; Disney A; Husbands SM; Traynor JR; Rice KC; Jutkiewicz EM
J Pharmacol Exp Ther; 2020 Aug; 374(2):319-330. PubMed ID: 32467352
[TBL] [Abstract][Full Text] [Related]
25. Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice.
Ide S; Minami M; Satoh M; Uhl GR; Sora I; Ikeda K
Neuropsychopharmacology; 2004 Sep; 29(9):1656-63. PubMed ID: 15100703
[TBL] [Abstract][Full Text] [Related]
26. Synthesis, opioid receptor binding, and functional activity of 5'-substituted 17-cyclopropylmethylpyrido[2',3':6,7]morphinans.
Ananthan S; Kezar HS; Saini SK; Khare NK; Davis P; Dersch CM; Porreca F; Rothman RB
Bioorg Med Chem Lett; 2003 Feb; 13(3):529-32. PubMed ID: 12565965
[TBL] [Abstract][Full Text] [Related]
27. Endogenous opioid peptides contribute to antinociceptive potency of intrathecal [Dmt1]DALDA.
Szeto HH; Soong Y; Wu D; Qian X; Zhao GM
J Pharmacol Exp Ther; 2003 May; 305(2):696-702. PubMed ID: 12606628
[TBL] [Abstract][Full Text] [Related]
28. Highly selective fluorescent analogue of the potent delta-opioid receptor antagonist Dmt-Tic.
Balboni G; Salvadori S; Dal Piaz A; Bortolotti F; Argazzi R; Negri L; Lattanzi R; Bryant SD; Jinsmaa Y; Lazarus LH
J Med Chem; 2004 Dec; 47(26):6541-6. PubMed ID: 15588089
[TBL] [Abstract][Full Text] [Related]
29. Effects of differential modulation of mu-, delta- and kappa-opioid systems on bicuculline-induced convulsions in the mouse.
Yajima Y; Narita M; Takahashi-Nakano Y; Misawa M; Nagase H; Mizoguchi H; Tseng LF; Suzuki T
Brain Res; 2000 Apr; 862(1-2):120-6. PubMed ID: 10799676
[TBL] [Abstract][Full Text] [Related]
30. 3-(alphaR)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-alkyl-N-arylbenzamides: potent, non-peptidic agonists of both the micro and delta opioid receptors.
Bishop MJ; Garrido DM; Boswell GE; Collins MA; Harris PA; McNutt RW; O'Neill SJ; Wei K; Chang KJ
J Med Chem; 2003 Feb; 46(4):623-33. PubMed ID: 12570383
[TBL] [Abstract][Full Text] [Related]
31. [2',6'-Dimethyltyrosine]dynorphin A(1-11)-NH2 analogues lacking an N-terminal amino group: potent and selective kappa opioid antagonists.
Lu Y; Nguyen TM; Weltrowska G; Berezowska I; Lemieux C; Chung NN; Schiller PW
J Med Chem; 2001 Sep; 44(19):3048-53. PubMed ID: 11543672
[TBL] [Abstract][Full Text] [Related]
32. SNC 80, a selective, nonpeptidic and systemically active opioid delta agonist.
Bilsky EJ; Calderon SN; Wang T; Bernstein RN; Davis P; Hruby VJ; McNutt RW; Rothman RB; Rice KC; Porreca F
J Pharmacol Exp Ther; 1995 Apr; 273(1):359-66. PubMed ID: 7714789
[TBL] [Abstract][Full Text] [Related]
33. Side chain methyl substitution in the delta-opioid receptor antagonist TIPP has an important effect on the activity profile.
Tourwé D; Mannekens E; Diem TN; Verheyden P; Jaspers H; Tóth G; Péter A; Kertész I; Török G; Chung NN; Schiller PW
J Med Chem; 1998 Dec; 41(26):5167-76. PubMed ID: 9857087
[TBL] [Abstract][Full Text] [Related]
34. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
Baker AK; Meert TF
J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
[TBL] [Abstract][Full Text] [Related]
35. Comparison of peptidic and nonpeptidic delta-opioid agonists on guanosine 5'-O-(3-[35S]thio)triphosphate ([35S]GTPgammaS) binding in brain slices from Sprague-Dawley rats.
Jutkiewicz EM; Walker NP; Folk JE; Rice KC; Portoghese PS; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2005 Mar; 312(3):1314-20. PubMed ID: 15574687
[TBL] [Abstract][Full Text] [Related]
36. Delta opioid antagonist effects of buprenorphine in rhesus monkeys.
Negus SS; Bidlack JM; Mello NK; Furness MS; Rice KC; Brandt MR
Behav Pharmacol; 2002 Nov; 13(7):557-70. PubMed ID: 12409994
[TBL] [Abstract][Full Text] [Related]
37. Development of potent bifunctional endomorphin-2 analogues with mixed mu-/delta-opioid agonist and delta-opioid antagonist properties.
Fujita Y; Tsuda Y; Li T; Motoyama T; Takahashi M; Shimizu Y; Yokoi T; Sasaki Y; Ambo A; Kita A; Jinsmaa Y; Bryant SD; Lazarus LH; Okada Y
J Med Chem; 2004 Jul; 47(14):3591-9. PubMed ID: 15214786
[TBL] [Abstract][Full Text] [Related]
38. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
[TBL] [Abstract][Full Text] [Related]
39. CI-977, a novel and selective agonist for the kappa-opioid receptor.
Hunter JC; Leighton GE; Meecham KG; Boyle SJ; Horwell DC; Rees DC; Hughes J
Br J Pharmacol; 1990 Sep; 101(1):183-9. PubMed ID: 2178014
[TBL] [Abstract][Full Text] [Related]
40. Opioid receptor activity of GI 87084B, a novel ultra-short acting analgesic, in isolated tissues.
James MK; Feldman PL; Schuster SV; Bilotta JM; Brackeen MF; Leighton HJ
J Pharmacol Exp Ther; 1991 Nov; 259(2):712-8. PubMed ID: 1658308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
